Acadian Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Acadian Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$39K	Buy	+677	New	+$31.2K	﹤0.01%	1884
2021 Q3	–	Sell	-2,365	Closed	-$44K	–	2053
2021 Q2	$44K	Sell	2,365 -24,288	-91%	-$448K	﹤0.01%	1821
2021 Q1	$476K	Sell	26,653 -50,705	-66%	-$859K	﹤0.01%	1214
2020 Q4	$1.19M	Sell	77,358 -5,359	-6%	-$62.7K	﹤0.01%	934
2020 Q3	$915K	Buy	82,717 +21,789	+36%	+$256K	﹤0.01%	939
2020 Q2	$762K	Buy	60,928 +55,244	+972%	+$703K	﹤0.01%	1052
2020 Q1	$64K	Buy	+5,684	New	+$80.9K	﹤0.01%	1455
2015 Q4	–	Sell	-10,474	Closed	-$86K	–	1522
2015 Q3	$86K	Sell	10,474 -11,652	-53%	-$116K	﹤0.01%	1006
2015 Q2	$255K	Buy	22,126 +18,237	+469%	+$252K	﹤0.01%	896
2015 Q1	$65K	Buy	3,889 +308	+9%	+$5.69K	﹤0.01%	1064
2014 Q4	$71K	Buy	+3,581	New	+$52.6K	﹤0.01%	1034

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acadian Asset Management's XENE Position: Q1 2026 in Review

Acadian Asset Management opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 677 shares worth $39K. The stake represents ﹤0.01% of the portfolio and ranks #1884 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in XENE as recently as Q2 2021.

Acadian Asset Management first reported a position in XENE in Q4 2014 and has held it in 11 quarters since. The position peaked at $1.19M in Q4 2020. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Acadian Asset Management held 677 shares of Xenon Pharmaceuticals worth $39K as of Q1 2026.
Xenon Pharmaceuticals was a new Acadian Asset Management position in Q1 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1884 holding.
Acadian Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2014 and has held it in 11 quarters since.
Acadian Asset Management's Xenon Pharmaceuticals position peaked at $1.19M in Q4 2020.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.